Interferon beta-1b
Interferon beta-1b

Interferon beta-1b, a treatment for Multiple Sclerosis

Multiple Sclerosis or “MS” is a demyelinating disease that occurs in the central nervous system consisting of the brain, spinal cord and optic nerve. It is an autoimmune disease in which the patient’s own immune system attacks healthy cells and tissues. Although the cause has not yet been explained, several studies have shown that genetic and environmental factors can play a complex role and at this time there is no known to treatment for multiple sclerosis and it can be alleviated by periodic administration of interferon beta injections.

Our Interferon beta-1b is the most advance stage of all Biocure Technology’s products. The pre-clinic trial started last year and is expected to be finished in the Fall of 2018.

Current Market Conditions:

  • The Multiple Sclerosis Market size in 2017 was approximately USD 21.5 billion
  • One of blockbuster bio-similar
  • There are currently only three main competitors in the world
  • Patients are predominantly in developed countries such as North America and Western Europe, as well as in the Middle East, North Africa, Eastern Europe, and South America.

Status of Current Development

  • Completed the preparation for mass production
  • Plan to begin clinical trial in 2018
  • The clinical trial is expected to take 18 – 24 months

Market Entry Strategy

  • Middle Eastern, North African and Brazil markets first
  • Main production item in the joint venture company in Turkey and Brazil
  • Current market average sales price is about USD 350/vial
  • Manufacturing cost is extremely low compare to selling price

Entry Barrier

  • It takes 18-24 months to complete clinical trial process

Ranibizumab
Ranibizumab

Ranibizumab

Current Market Conditions:

  • Market entered with the name “Lucentis” by Novatis
  • Annual market size of USD 1.3 billion as of 2009
  • High priced antibiotic bio medical drug of USD 1200 for 3mg/vial
  • High demand, it can be one of blockbuster biopharmaceuticals
  • Manufacturing cost is extremely low compare to selling price

Status of Current Development

  • It can be produced by recombinant E. coli
  • Pre-clinical trial is going to start in 2018 and commercialized in 2019 or early of 2020

Market Entry Strategy

  • We will produce this product as best quality
  • We will launch this product in the Korean market first and we will export this emerging countries
  • For oversea market, export is going to be actively done to where company’s partners are, which are Eastern Europe, Brazil, Middle East, Southeast Asia and Turkey etc.

Entry Barrier

  • Starting pre-clinical trial as soon as possible (pre-clinical trial will be start within 2018)

Ranibizumab graph

PEG-Filgrastim (G-CSF)
PEG-Filgrastim (PEG-GCSF)

PEG-Filgrastim (PEG-GCSF) for treatment of Neutropenia

Neutropenia  is an abnormally low level of neutrophils. Neutrophils are a common type of white blood cell important to fighting off infections — particularly those caused by bacteria. For adults, counts of less than 1,500 neutrophils per microliter of blood are considered to be neutropenia.

Current Market Conditions:

  • Filgrastim is an anti-cancer treatment which plays an important role in the recovery of the cancer patient’s immunity
  • Amgen created a market of USD 6 billion or more by selling first general drug called Neupogen
  • Sales and proportion of Neulbasta (PEG-GCSF) are increasing in total market for GCSF
  • Multiple number of companies produce the first generation Filgrastim

Status of Current Development

  • Secured production technology of the first generation of Filgrastim
  • Pre-clinical and clinical period is expected to take about 30 months

Market Entry Strategy

  • Biocure will launch this product in Middle East, Eastern Europe, Turkey, Thailand and Malaysia through oversea partners as first stage
  • Price competitiveness with best quality

Entry Barrier

  • Takes 30 months to complete pre-clinical and clinical trial